Perfromance Wealth Partners’s AbbVie ABBV Stock Holding History

Perfromance Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.72M	Sell	26,318 -906	-3%	-$201K	0.17%	28
2025 Q4	$6.22M	Sell	27,224 -1,045	-4%	-$238K	0.17%	27
2025 Q3	$6.55M	Sell	28,269 -461	-2%	-$93.9K	0.18%	27
2025 Q2	$5.33M	Sell	28,730 -6	-0%	-$1.11K	0.17%	29
2025 Q1	$6.02M	Sell	28,736 -4,799	-14%	-$933K	0.22%	26
2024 Q4	$5.96M	Sell	33,535 -413	-1%	-$75.9K	0.19%	24
2024 Q3	$6.7M	Sell	33,948 -816	-2%	-$152K	0.23%	25
2024 Q2	$5.96M	Sell	34,764 -1,505	-4%	-$249K	0.22%	23
2024 Q1	$6.6M	Sell	36,269 -2,082	-5%	-$359K	0.28%	28
2023 Q4	$5.94M	Sell	38,351 -7,201	-16%	-$1.05M	0.26%	30
2023 Q3	$6.79M	Sell	45,552 -1,702	-4%	-$250K	0.33%	31
2023 Q2	$6.5M	Buy	47,254 +413	+0.9%	+$60.6K	0.3%	29
2023 Q1	$7.47M	Sell	46,841 -24	-0.1%	-$3.67K	0.38%	25
2022 Q4	$7.57M	Sell	46,865 -4,258	-8%	-$653K	0.46%	25
2022 Q3	$6.86M	Sell	51,123 -78	-0.2%	-$11.2K	0.4%	27
2022 Q2	$7.84M	Sell	51,201 -3,039	-6%	-$464K	0.44%	26
2022 Q1	$8.79M	Buy	54,240 +199	+0.4%	+$28.9K	0.38%	27
2021 Q4	$7.32M	Buy	+54,041	New	+$6.38M	0.3%	34

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perfromance Wealth Partners's ABBV Position: Q1 2026 in Review

Perfromance Wealth Partners reduced its AbbVie (ABBV) stake by 3.3% in Q1 2026, selling an estimated $201K and leaving 26,318 shares worth $5.72M. The position accounts for 0.17% of the portfolio, ranked #28.

Perfromance Wealth Partners first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. The position peaked at $8.79M in Q1 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Perfromance Wealth Partners held 26,318 shares of AbbVie worth $5.72M as of Q1 2026.
Perfromance Wealth Partners sold 906 AbbVie shares in Q1 2026, an estimated $201K.
AbbVie made up 0.17% of Perfromance Wealth Partners's portfolio in Q1 2026, its #28 holding.
Perfromance Wealth Partners first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
Perfromance Wealth Partners's AbbVie position peaked at $8.79M in Q1 2022.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Perfromance Wealth Partners's 13F filing for Q1 2026, filed 10 Apr 2026.